CFLAR and endometrial carcinoma: A previous study reported that inhibition of CK-2 by TBB decreased the endogenous cFLIP levels via proteasome-mediated degradation of cFLIP, leading to the enhancement of TRAIL and FAS sensitivity in endometrial carcinoma cells [10].